Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
1 clinical trials · Condition
◉ Watch Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level
| Record | Firm | Date |
|---|---|---|
| Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation (NCT03881735) | Roswell Park Cancer Institute | 2019-12-02 |
Track Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level automatically
Every clearance here is in the API, with alerts when new ones post.